Literature DB >> 7481481

Longitudinal study on the production of and cellular response to interleukin-2 in patients with systemic lupus erythematosus.

J Alcocer-Varela1, D Alarcón-Segovia.   

Abstract

Interleukin-2 (IL-2) has been proven to be a defective element in immune regulation in systemic lupus erythematosus (SLE). However, its course in time is unknown. We studied its production and cellular response in the peripheral blood cells of 30 SLE patients and 12 healthy subjects. In addition, we studied the spontaneous and lipopolysaccharide (LPS) induced production of IL-1, which have been found to be, respectively, increased and lowered in untreated SLE patients. Patients were studied at the outset, when still untreated, and at 1, 2, 6, 12, 18, and 24 months. At the outset, 18 had active disease and 12 were in remission. The decreased proliferative response of T cells to IL-2 and the deficient production of IL-1 upon LPS induction became normal after 6 months treatment, whereas the expression of high affinity IL-2 receptors took 18 months to become normal and the deficient production of IL-2 took 2 years. Despite clinical remission, the decreased capacity of T cells to absorb IL-2 persisted for 2 years. The effect of various prednisone dosages on the measured variables was evaluated. With intermediate doses of prednisone (20-45 mg), we observed the largest improvement in IL-2 production and in IL-1 production upon LPS stimulation. Higher doses of prednisone reduced also the spontaneous production of IL-1 and resulted in an increase in the expression of CD25+ cells. The addition of low doses of cytotoxic drugs (oral cyclophosphamide or azathioprine) resulted in an improvement in the capacity to absorb IL-2 and a reduction in spontaneous IL-1 production.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7481481     DOI: 10.1007/bf00262709

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  22 in total

1.  The biology and clinical applications of interleukin 2.

Authors:  R C Rees; R H Wiltrout
Journal:  Immunol Today       Date:  1990-02

Review 2.  The connective tissue diseases as disorders of immune regulation.

Authors:  D Alarcon-Segovia; J Alcocer-Varela; E Diaz-Jouanen
Journal:  Clin Rheum Dis       Date:  1985-12

3.  Cloning of the gamma chain of the human IL-2 receptor.

Authors:  T Takeshita; H Asao; K Ohtani; N Ishii; S Kumaki; N Tanaka; H Munakata; M Nakamura; K Sugamura
Journal:  Science       Date:  1992-07-17       Impact factor: 47.728

4.  Defective expression of p70/75 interleukin 2 receptor in T cells from patients with systemic lupus erythematosus: a possible defect in the process of increased intracellular calcium leading to p70/75 expression.

Authors:  O Saiki; T Tanaka; S Kishimoto
Journal:  J Rheumatol       Date:  1990-10       Impact factor: 4.666

5.  Differences in the kinetics of the autologous mixed lymphocyte reaction between the various connective tissue diseases.

Authors:  A Laffón; J Alcocer-Varela; D Alarcón-Segovia
Journal:  Rheumatol Int       Date:  1983       Impact factor: 2.631

6.  Studies of immune functions of patients with systemic lupus erythematosus. T-cell subsets and antibodies to T-cell subsets.

Authors:  T Sakane; A D Steinberg; J P Reeves; I Green
Journal:  J Clin Invest       Date:  1979-11       Impact factor: 14.808

7.  HLA-DP+ T cells and deficient interleukin-2 production in patients with systemic lupus erythematosus.

Authors:  T Hishikawa; Y Tokano; I Sekigawa; S Ando; Y Takasaki; H Hashimoto; S Hirose; K Okumura; M Abe; T Shirai
Journal:  Clin Immunol Immunopathol       Date:  1990-05

8.  Two types of antibodies inhibiting interleukin-2 production by normal lymphocytes in patients with systemic lupus erythematosus.

Authors:  J Miyagi; N Minato; M Sumiya; T Kasahara; S Kano
Journal:  Arthritis Rheum       Date:  1989-11

9.  Further characterization of interleukin-2 production by lymphocytes of patients with systemic lupus erythematosus.

Authors:  M Linker-Israeli; F P Quismorio; D A Horwitz
Journal:  J Rheumatol       Date:  1988-08       Impact factor: 4.666

10.  Characterization of T lymphocyte subpopulations responsible for deficient interleukin 2 activity in patients with systemic lupus erythematosus.

Authors:  Y Murakawa; S Takada; Y Ueda; N Suzuki; T Hoshino; T Sakane
Journal:  J Immunol       Date:  1985-01       Impact factor: 5.422

View more
  4 in total

Review 1.  The contribution of interleukin-2 to effective wound healing.

Authors:  Karen M Doersch; Daniel J DelloStritto; M Karen Newell-Rogers
Journal:  Exp Biol Med (Maywood)       Date:  2016-10-25

2.  Quantitative and functional profiles of CD4+ lymphocyte subsets in systemic lupus erythematosus patients with lymphopenia.

Authors:  D Gómez-Martín; M Díaz-Zamudio; G Vanoye; J C Crispín; J Alcocer-Varela
Journal:  Clin Exp Immunol       Date:  2011-01-14       Impact factor: 4.330

3.  CTL-promoting effects of CD40 stimulation outweigh B cell-stimulatory effects resulting in B cell elimination and disease improvement in a murine model of lupus.

Authors:  Roman Puliaev; Irina Puliaeva; Lisbeth A Welniak; Abigail E Ryan; Mark Haas; William J Murphy; Charles S Via
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

4.  Chronic Immune Activation in Systemic Lupus Erythematosus and the Autoimmune PTPN22 Trp620 Risk Allele Drive the Expansion of FOXP3+ Regulatory T Cells and PD-1 Expression.

Authors:  Ricardo C Ferreira; Xaquin Castro Dopico; João J Oliveira; Daniel B Rainbow; Jennie H Yang; Dominik Trzupek; Sarah A Todd; Mhairi McNeill; Maristella Steri; Valeria Orrù; Edoardo Fiorillo; Daniel J M Crouch; Marcin L Pekalski; Francesco Cucca; Tim I Tree; Tim J Vyse; Linda S Wicker; John A Todd
Journal:  Front Immunol       Date:  2019-11-08       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.